Literature DB >> 15446585

Gene expression profiling reveals unique molecular subtypes of Neurofibromatosis Type I-associated and sporadic malignant peripheral nerve sheath tumors.

Mark A Watson1, Arie Perry, Tarik Tihan, Richard A Prayson, Abhijit Guha, Julia Bridge, Rosalie Ferner, David H Gutmann.   

Abstract

Malignant peripheral nerve sheath tumors (MPNSTs) are highly aggressive Schwann cell neoplasms that are frequently associated with Type I Neurofibromatosis (NF1) and respond poorly to current therapeutic regimens. To better understand the molecular heterogeneity of these tumors, we performed gene expression profiling on 25 NF1-associated and 17 sporadic MPNSTs using oligonucleotide microarrays representing approximately 8100 unique human gene transcripts. Using several previously reported statistical approaches, we were unable to identify a molecular signature that could reliably distinguish between NF1-associated and sporadic MPNSTs in independent training and test sample sets. However, using an unsupervised clustering approach, we identified an extensive gene expression signature that distinguished 9 of the 42 tumors analyzed. This signature corresponded to relative overexpression of transcripts associated with neuroglial differentiation (NCAM, MBP, L1CAM, P1P) and relative down-regulation of proliferation and growth factor associated transcripts (IGF2, FGFR1, MDK, Ki67). All tumors with this gene expression signature lacked expression of EGFR and all but one tumor were derived from patients with NF1. However, there were no other obvious associations with histological grade, tumor site, metastasis, recurrence, age, or patient survival. We conclude that distinct molecular classes of MPNST exist and that the ability to stratify these tumors based on unique and biologically relevant gene expression profiles may be important for future targeted therapeutics.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15446585     DOI: 10.1111/j.1750-3639.2004.tb00067.x

Source DB:  PubMed          Journal:  Brain Pathol        ISSN: 1015-6305            Impact factor:   6.508


  28 in total

1.  Histopathology and clinical outcome of NF1-associated vs. sporadic malignant peripheral nerve sheath tumors.

Authors:  Christian Hagel; Ulrich Zils; Matthias Peiper; Lan Kluwe; Stefan Gotthard; Reinhard E Friedrich; David Zurakowski; Andreas von Deimling; Victor Felix Mautner
Journal:  J Neurooncol       Date:  2006-11-17       Impact factor: 4.130

Review 2.  Current status of sporadic and neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors.

Authors:  Brigitte C Widemann
Journal:  Curr Oncol Rep       Date:  2009-07       Impact factor: 5.075

3.  Gene expression profiles in acute myeloid leukemia with common translocations using SAGE.

Authors:  Sanggyu Lee; Jianjun Chen; Guolin Zhou; Run Zhang Shi; Gerard G Bouffard; Masha Kocherginsky; Xijin Ge; Miao Sun; Nimanthi Jayathilaka; Yeong Cheol Kim; Neelmini Emmanuel; Stefan K Bohlander; Mark Minden; Justin Kline; Ozden Ozer; Richard A Larson; Michelle M LeBeau; Eric D Green; Jeffery Trent; Theodore Karrison; Piu Paul Liu; San Ming Wang; Janet D Rowley
Journal:  Proc Natl Acad Sci U S A       Date:  2006-01-17       Impact factor: 11.205

4.  Ras-driven transcriptome analysis identifies aurora kinase A as a potential malignant peripheral nerve sheath tumor therapeutic target.

Authors:  Ami V Patel; David Eaves; Walter J Jessen; Tilat A Rizvi; Jeffrey A Ecsedy; Mark G Qian; Bruce J Aronow; John P Perentesis; Eduard Serra; Timothy P Cripe; Shyra J Miller; Nancy Ratner
Journal:  Clin Cancer Res       Date:  2012-07-18       Impact factor: 12.531

Review 5.  The role of the immune system in neurofibromatosis type 1-associated nervous system tumors.

Authors:  Souvik Karmakar; Karlyne M Reilly
Journal:  CNS Oncol       Date:  2016-12-21

6.  Whole Exome Sequencing Reveals the Order of Genetic Changes during Malignant Transformation and Metastasis in a Single Patient with NF1-plexiform Neurofibroma.

Authors:  Angela C Hirbe; Sonika Dahiya; Christopher A Miller; Tiandao Li; Robert S Fulton; Xiaochun Zhang; Sandra McDonald; Katherine DeSchryver; Eric J Duncavage; Jessica Walrath; Karlyne M Reilly; Haley J Abel; Melike Pekmezci; Arie Perry; Timothy J Ley; David H Gutmann
Journal:  Clin Cancer Res       Date:  2015-04-29       Impact factor: 12.531

7.  MicroRNA-204 critically regulates carcinogenesis in malignant peripheral nerve sheath tumors.

Authors:  Meng Gong; Junrong Ma; Mi Li; Mingliang Zhou; Janet M Hock; Xijie Yu
Journal:  Neuro Oncol       Date:  2012-06-19       Impact factor: 12.300

8.  Genome-wide transcriptome analyses reveal p53 inactivation mediated loss of miR-34a expression in malignant peripheral nerve sheath tumours.

Authors:  Subbaya Subramanian; Venugopal Thayanithy; Robert B West; Cheng-Han Lee; Andrew H Beck; Shirley Zhu; Erinn Downs-Kelly; Kelli Montgomery; John R Goldblum; Pancras C W Hogendoorn; Christopher L Corless; Andre M Oliveira; Sarah M Dry; Torsten O Nielsen; Brian P Rubin; Jonathan A Fletcher; Christopher D M Fletcher; Matt van de Rijn
Journal:  J Pathol       Date:  2010-01       Impact factor: 7.996

9.  Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors.

Authors:  Gunnar Johansson; Yonatan Y Mahller; Margaret H Collins; Mi-Ok Kim; Takahiro Nobukuni; John Perentesis; Timothy P Cripe; Heidi A Lane; Sara C Kozma; George Thomas; Nancy Ratner
Journal:  Mol Cancer Ther       Date:  2008-05       Impact factor: 6.261

10.  Inhibition of Eyes Absent Homolog 4 expression induces malignant peripheral nerve sheath tumor necrosis.

Authors:  S J Miller; Z D Lan; A Hardiman; J Wu; J J Kordich; D M Patmore; R S Hegde; T P Cripe; J A Cancelas; M H Collins; N Ratner
Journal:  Oncogene       Date:  2009-11-09       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.